<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03126071</url>
  </required_header>
  <id_info>
    <org_study_id>RBACC</org_study_id>
    <nct_id>NCT03126071</nct_id>
  </id_info>
  <brief_title>Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer</brief_title>
  <official_title>A Phase II Study of Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Cancer Institute &amp; Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Cancer Institute &amp; Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to investigate the efficacy and safety of raltitrexed-based chemotherapy
      plus bevacizumab in the treatment of advanced colorectal cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2017</start_date>
  <completion_date type="Anticipated">February 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>6 months</time_frame>
    <description>Progression Free Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>15 months</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>36 months</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>36 months</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs</measure>
    <time_frame>36 months</time_frame>
    <description>Percentage of participants experiencing grade 3-5 adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Advanced Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Raltitrexed and Irinotecan（RALIRI） plus Bevacizumab(AVASTIN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan:250mg/m2 iv,90min,d1, Raltitrexed:3.0mg/m2,iv,15min,d1, Bevacizumab:7.5mg/kg iv,30min,d1,q3w. Maintenance: Raltitrexed(3.0mg/m2,iv,15min,d1,q3w)+Bevacizumab(7.5 mg/kg q3w)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Raltitrexed and Oxaliplatin（RALOX） plus Bevacizumab(AVASTIN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin:130mg/m2 iv,120min,d1, Raltitrexed:3.0mg/m2,iv,15min,d1, Bevacizumab:7.5mg/kg iv,30min,d1,q3w. Maintenance: Raltitrexed(3.0mg/m2,iv,15min,d1,q3w)+Bevacizumab(7.5 mg/kg q3w)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltitrexed</intervention_name>
    <description>Raltitrexed:3mg/m2,iv 15min,d1,q3w.</description>
    <arm_group_label>Raltitrexed and Irinotecan（RALIRI） plus Bevacizumab(AVASTIN)</arm_group_label>
    <arm_group_label>Raltitrexed and Oxaliplatin（RALOX） plus Bevacizumab(AVASTIN)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan:250mg/m2,iv 90min,d1,q3w.</description>
    <arm_group_label>Raltitrexed and Irinotecan（RALIRI） plus Bevacizumab(AVASTIN)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin:130mg/m2,iv 120min,d1,q3w.</description>
    <arm_group_label>Raltitrexed and Oxaliplatin（RALOX） plus Bevacizumab(AVASTIN)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab:75mg/kg,iv 30min,d1,q3w.</description>
    <arm_group_label>Raltitrexed and Irinotecan（RALIRI） plus Bevacizumab(AVASTIN)</arm_group_label>
    <arm_group_label>Raltitrexed and Oxaliplatin（RALOX） plus Bevacizumab(AVASTIN)</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-70 years;

          -  histological and/or cytological confirmation of ACC;

          -  disease progression while on first-line palliative fluoropyrimidine-based chemotherapy
             or relapse within 6 months after adjuvant chemotherapy;

          -  at least one measurable objective tumor lesion by spiral CT examination, the maximum
             diameter ≥ 1cm（according to RECIST 1.1）

          -  ECOG performance status 0-1

          -  life expectancy of at least 3 months

          -  satisfactory main organ function，laboratory test must meet the following criteria:
             hemoglobin (HGB) ≥90g/L, neutrophil count（ANC） ≥1.5×109/L, platelet count（PLT）
             ≥80×109/L, Serum creatinine（CR）≤1.5 upper normal limitation (UNL)，total bilirubin
             (TBil) ≤1.5 upper normal limitation (UNL), alanine aminotransferase (ALT) and
             aspartate aminotransferase (AST) ≤2.5 UNL (For patients with liver metastasis, the
             AST/ALT must be ≤5.0 UNL), Alkaline phosphatase（ALP）≤3 UNL(For patients with liver
             metastasis, the ALP must be ≤5.0 UNL);

          -  written informed consent

        Exclusion Criteria:

          -  prior exposure to bevacizumab or raltitrexed;

          -  Clinically significant cardiovascular disease, for example symptomatic coronary artery
             disease, myocardial infarction (&lt;=6 months before treatment start),congestive heart
             failure （New York Heart Association ，NYHA&gt;= grade 3）,stroke or transient ischemic
             attack

          -  Accept kidney dialysis treatment now

          -  chronic enteropathy on unresolved bowel obstruction;

          -  previous malignant disease other than carcinoma in situ of the cervix or basal cell
             carcinoma of the skin;

          -  the UGT1A1 *28（7/7）*6（A/A） gene type;

          -  pregnant or lactated women;

          -  Unsuitable for the study or other chemotherapy determined by investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Liangjun Zhu</last_name>
    <phone>+8613905199123</phone>
    <email>zhulj98@foxmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuejiao Zhong, M.D.</last_name>
    <phone>+8613770575447</phone>
    <email>zhongyuejiao@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jiangsu Cancer Institute &amp; Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liangjun Zhu</last_name>
      <phone>+8613905199123</phone>
      <email>zhulj98@foxmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yuejiao Zhong</last_name>
      <phone>+861370575447</phone>
      <email>zhongyuejiao@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nantong Tumor Hospital</name>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <zip>226000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lei Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chunrong Zhu, M.D.</last_name>
      <phone>+8613063870566</phone>
      <email>zcr050311@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Feng Xiong</last_name>
      <phone>+8613270971002</phone>
      <email>greenlemontea@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rui Jin Hospital Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jun Zhang, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2017</study_first_submitted>
  <study_first_submitted_qc>April 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2017</study_first_posted>
  <last_update_submitted>April 20, 2017</last_update_submitted>
  <last_update_submitted_qc>April 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jiangsu Cancer Institute &amp; Hospital</investigator_affiliation>
    <investigator_full_name>Liangjun Zhu M.M.</investigator_full_name>
    <investigator_title>Ward Director of Internal Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Raltitrexed</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

